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A B S T R A C TIn Latin America, social security and public sectors represent the
largest financiers and providers of health care. Many countries in the
region have compulsory packages of basic health care benefits. As
part of an effort to improve quality of care and access, several health
technology assessment agencies, both governmental and academia,
among a number of Latin American countries have been formally
established in the past few years. Several Latin American countries
have recently developed and published methodological guidelines in
economic evaluation, indicating that there is a growing interest in
evaluating health-related products, drugs, and technologies used by
the population. Presentations on the health care system and the role
of health technology assessment, pharmacoeconomics, and risk
sharing policies, from the public sector perspective, in the Latinnt matter Copyright & 2012, International Society
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.1016/j.vhri.2012.09.007
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made at the 3rd Latin American ISPOR Conference held in Mexico City
in 2011 and are discussed in this article. In conclusion, there is a clear
need for Latin American countries to evaluate the value of new
technologies that are being incorporated into their health care
system. In addition, health technology assessment guidelines are
important for their local needs in terms of regulation along with
common country unions. In the future, the Latin American region
needs to increase drug access along with implementing cost-
containment measures to improve quality and health outcomes.
Keywords: health technology assessment, Latin America.
Copyright & 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The health care system in Latin America is highly fragmented
and has subsystems that target specific strata of the population
grouped by social class, income, occupation, type of employment,
ethnic origin, or urban or rural residence, producing a phenom-
enon of population segregation that has led to higher segmenta-
tion, fragmentation, and low efficiency [1].
To address the fragmentation of the health care systems in
the region, the Organizacion Panamericana del Salud (Pan-American
Health Organization) created a new health technology assess-
ment (HTA) network in the Americas (Red de Evaluacio´n de
Tecnologı´as Sanitarias), which triggered the HTA development
in Latin America [1,2]. As part of this initiative, countries
representing Mercosur (Brazil, Argentina, Paraguay, and Uruguay)
and Grupo Andino (Bolivia, Chile, Colombia, Ecuador, Peru, and
Venezuela) commenced focusing their efforts on the implemen-
tation of HTA. Currently, Mercosur has guidelines for HTA
methods, new technologies, and economic evaluation. The GrupoAndino is also working toward developing methodological HTA
guidelines [1,2].
There are several HTA agencies, both governmental and
academia, among a number of Latin American countries, which
were formally established in the last couple of years. Countries
such as Cuba, Brazil, and Mexico have recently developed and
published methodological guidelines in economic evaluation,
indicating that there is a growing interest in evaluating health-
related products, drugs, and technologies used by the population
[3,4].
In 2009, during the 2nd ISPOR Latin America Conference held
in Rio de Janeiro, Brazil, the first symposia was held to discuss
questions on HTAs, decision-making reimbursement, and phar-
macoeconomics to support each country’s needs at that time,
with a focus on four Latin American countries (Argentina, Brazil,
Colombia, and Mexico) [5]. To provide an update on the informa-
tion presented in 2009, at the 3rd Latin America Conference
held in 2011 in Mexico City, Mexico, a second symposia served
to discuss the health care reimbursement environment andfor Pharmacoeconomics and Outcomes Research (ISPOR).
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countries (Argentina, Brazil, Colombia, and Mexico).
In Latin America, social security and public sectors represent
the largest financiers and providers of health care. Many coun-
tries in Latin America have compulsory packages of basic health
care benefits. What follows are country-specific updates of the
public sector environment in Argentina, Brazil, Colombia, and
Mexico concerned with the reimbursement environment and
HTA based on the presentations and discussions at the 2011 3rd
Latin American ISPOR Conference held in Mexico City [6].Mexico
The Mexican health care system is divided into public (social
security and Ministry of Health) and private (employers and self-
pay), with only 64.6% of its population having health insurance
[7]. The Mexican general law of health assigns to the Ministry
of Health the responsibility to elaborate Mexican official norms of
the sector and gather sanitary statistics. Under the Ministry
of Health, Mexico has a general health council, which is the body
of the Mexican state and is the health authority across the
country. The Mexican council is assigned the responsibility to
elaborate, review, and maintain permanent updates of the data of
formulary drugs and studies and serves to resolve requests for
updating the formulary drugs of the providers of health, scientific
organizations, and suppliers [7].
According to the general law of health, before each new
technology is introduced to the national market for its consump-
tion, it must first obtain a sanitary registry. This request is made
to the ‘‘Comisio´n Federal para la Proteccio´n contra Riesgos
Sanitarios’’ [8], a commission that evaluates safety and efficacy
of the product at issue.
Since 2000, once a product is in the national market it needs
to be included in the formulary called ‘‘Basic Formulary Medica-
tions’’ and medicine catalogue made available through the Public
System of Social Security. The private system of national health
has the freedom to use drugs that are not included among the
Basic Formulary Medications.
In 2007, to better evaluate health products and technologies
available to the Mexican population, a program of action specific
to HTA was established. HTA reports and recommendations are
provided by university research centers and medical societies to
the general health council and the minister of health to inform
the Ministry of Health, payers, and providers. Since 2003, phar-
macoeconomic studies are regarded as being mandatory as part
of the HTA submission. To ensure the quality of the economic
evaluations generated for the Council of General Salubrity, the
academy and the pharmaceutical industry published in 2008 the
‘‘Guide for the conduction of studies of economic evaluation for
the update of the Basic Formulary Medications of consumptions
of the health sector in Mexico’’ [9].
As of 2003, in Mexico, there has been a growth in the
development of economic evaluations with the intended purpose
to fulfill the requirements for inclusion to the Basic Formulary
Medications. These economic evaluations are, for the most part,
presented to providers who have requested an update of the
Basic Formulary Medications. Apart from those created by the
government, some of the economic evaluations are also per-
formed by academic groups and private consultants.
To perform HTAs in Mexico, the Center of National Health
Technology (Centro Nacional de Excelencia Tecnolo´gica en Salud)
was instituted, which is a Ministry of Health agency. Its main
purpose is to produce objective, reliable, and timely information
related to health technologies. It is organized into three main
programs: 1) medical equipment planning, to provide informa-
tion on medical equipment as well as to supply the NationalHealth Care System with information on the incorporation
of medical devices; 2) the HTA, generating evidence to aid decision
making from the Ministry of Health and the general health council;
and 3) e-Health, to generate health information to the national
health care system and communication of technologies [10].Brazil
The Brazilian Constitution (1988) states that the country is respon-
sible for providing heath care access to every Brazilian citizen [11].
For this reason, the Brazilian health care system is composed of a
public mandatory, tax-based unified system (Sistema U´nico de
Sau´de) as well as an optional, premium-based private health care
system, frequently provided through employers representing
75% of the private care system. The Brazilian health care system
is organized into three categories: 1) the Ministry of Health
(major policies), representing the entire country; 2) state secre-
taries of health, representing on a state level; and 3) municipal
secretaries of health, on the city level (general practice, primary
care services) [12].
The Ministry of Health is responsible for the development of a
formulary, listing the drugs to be available to the entire Brazilian
population at no cost to the patient in what is called RENAME
(essential drug list). RENAME contains drugs that are approved by
Ageˆncia Nacional de Vigilaˆncia sanita´ria (ANVISA), have proven
effectiveness, and are indicated for diseases that affect a large
population. In the past decade, another list was created to cover
exceptional drugs or high-cost drugs that, after evaluation by the
Ministry of Health, are considered effective and needed, and must
be available at no cost for the entire Brazilian population [13].
There are two regulatory agencies, the National Agency for
Private Health Care (ANS) and the National Health Surveillance
Agency (ANVISA) [14,15]. ANS is an agency that oversees the
relationship between patients and insurance companies to
ensure transparency [15]. ANVISA is responsible for licensing,
registering, and pricing of drugs, devices, equipments, and
medical products in the country. It is illegal for patients in Brazil
to consume drugs or utilize procedures that are not regulated and
approved by ANVISA [16]. Until 2003, ANVISA would make
decisions based exclusively on safety and effectiveness; however,
in 2003, a governmental council that aims to economically
regulate the market of drugs in Brazil (Chamber of Medicine)
was created to evaluate the price of new health products as well
as establish a cap to the annual price increase for drugs [17].
In December 2006, the Ministry of Health approved a national
policy to evaluate and manage health care technologies requiring a
description of technology, identification of submitter, number of
ANVISA registry, proposed price approved by ANVISA, technical
report presenting the scientific evidence of safety, efficacy/effective-
ness comparing the proposed technology with the available and
current technology, economic evaluation (cost-effectiveness and cost-
utility evaluation) when there is a trade-off involving effectiveness,
costs, and a budget impact analysis; however, it is market driven.
In 2011, the Brazilian Congress approved a new bill establish-
ing the following [16]:1. The establishment of the National Council for the Incorpora-
tion of Medicines and Products for Health (Comiss ~ao Nacional
de Incorporac- ~ao de Tecnologias [CONITEC]) in substitution of
the Commission for Incorporation of Technologies. CONITEC
includes representatives of Ministry of Health secretaries,
ANVISA, ANS, National Council of Health Secretaries,
National Council of Municipal Health Secretaries, and Federal
Council of Medicine.2. Decisions for listing products should be completed within
180 þ 90 days after the submission of the dossier.
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available in the health care system within 180 days.3. Dossiers can be submitted to CONITEC throughout the year.
4. Medicines and products for health should be used according
to the clinical guidelines approved by the Ministry of Health.
5. It is illegal to list, pay for, or reimburse any drug or procedure
not registered by ANVISA.
Currently, risk-sharing negotiations/proposals are not part of
the approval and decision-making process and have rarely been
discussed at Brazilian scientific meetings, pharmaceutical com-
panies, or academia. According to the current Brazilian regula-
tion, risk-sharing negotiations are not allowed but discussions
regarding these programs have started and the scenario may
potentially change in the next few years. Brazil has a two-step
decision process when defining costs. The first step is performed
by ANVISA and considers safety, efficacy, and price. At this point,
ANVISA will use international reference pricing. The second step
commences once the drug is approved by ANVISA and is ready to
be commercialized in Brazil, whereby the Ministry of Health,
through the CONITEC, utilizes HTA data to define whether a drug
should be included in the formulary and therefore available at no
cost to all appropriate patients. There is no official threshold to
guide decision making with regard to cost-effectiveness and the
decision of including a drug on the formulary [15–17].Argentina
Argentina is a federal country with 40 million people and 24
provinces. For this reason, the Argentine health care system is
highly fragmented, whereby each of the 24 provinces has its own
health care system. Social security (obras sociales), provided by
300 organizations, covers 47% of the health care expenses,
followed by the public sector (35%), private sector (10%), and
Instituto Nacional de Servicios Sociales para Jubilados y Pensio-
nados, which is insurance to the elderly, which serves 8% of the
population. Currently, the Ministry of Health and social security
are the biggest consumers of health information [18].
HTA activities are thus decentralized, without a national HTA
agency or health economic guidelines. In 2009, a governmental unit
was created to coordinate HTA effortswithin national bodies: the de
Evaluacio´n y Ejecucio´n de Tecnologı´as en Salud or The National
Coordination Unit of Health Technology Assessment and Imple-
mentation. The de Evaluacio´n y Ejecucio´n de Tecnologı´as en Salud
is formed by representatives of 12 areas of the Ministry of Health,
ranging from the national regulatory agency (Administracio´n Nacio-
nal de Medicamentos, Alimentos y Tecnologı´a Me´dica), the Super-
intendence of Social Services that regulates social security, national
hospitals, to Instituto Nacional de Servicios Sociales para Jubilados
y Pensionados (the elderly insurance). Its main objectives are to
coordinate the different bodies to ensure access to HTA information
to health authorities and citizens [19].
The Superintendence of Health is the body that regulates the
social security sector and has a compulsory package of services
(Programa Me´dico Obligatorio) whose creation was informed by
HTA principles. A recent law was passed in 2011 to regulate
private health insurances as well.
The Instituto de Effectividad Clı´nica y Sanitaria is an International
Network of Agencies for Health Technology Assessment–affiliated
HTA agency in Argentina with an active role in HTA activities in
Argentina and Latin America and the Caribbean region. It has
published more than 120 publications in peer-review journals and
more than 200 HTAs that are indexed at the Centre for Reviews and
Dissemination of the University of York. Forty percent of the HTA
documents were on intervention procedures such as implantable
cardiodefibrillators, prosthetic intervertebral discs, and deep brainstimulation. Twenty percent of the documents evaluated diagnostic
technologies such as positron emission tomography, multislice
computed tomography, and hip arthroscopy, and the remaining
40% evaluated drugs such as gefitinib, etanercept, cetuximab, and
interferon [20].
Even though Argentina was the first country in the region to
require formal health economic evidence for the adoption of
technologies into the mandatory benefit package of social security,
this is no longer required. Nevertheless, there is an increasing
interest and demand for a more explicit and transparent resource-
allocation process that includes HTA as a formal tool to inform
decision making, in most of Argentine health care stakeholders.Colombia
In Colombia, health care expenditures represented approxi-
mately 6.9%, 7.6%, and 7.6% of its gross domestic product (about
$377, $392, and $472 per capita in health care) in 2008, 2009, and
2010, respectively [21,22].
The Colombian health care system, since 1993, is based on
compulsory insurance whereby the government mediates and
controls the health care system in the country. Law 100 establishes
that the Ministry of Health is responsible for the coordination,
control, and direction of centers of health. Health insurance in the
country can be viewed as part of a contributory system, for people
with formal employment, or a subsidized system, for a low-income
population. People from both systems can benefit from health
providing institutions Empresas Promotoras de Salud [EPS] includ-
ing hospitals, clinics, laboratories, and pharmaceutical services [23].
This law also requested the creation of the National Institute for
Drug and Food Surveillance Colombia, or Instituto Nacional de
Vigilancia de Medicamentos y Alimentos, the agency responsible for
the regulation and approval of drugs for use in the country [23].
In 2007, the Colombian Congress approved the creation of a
Health Regulation Commission La Comisio´n de Regulacio´n en
Salud (CRES) [24]. It was established to define and modify a
compulsory basic health care plan (POS); to define the unit of
capitation payment (premium that the system pays to the EPS to
finance POS) for the contributory and subsidized systems per
annum; to define the payment criteria for the payments provided
in order to regulate the access to health services; and to establish
and update on an annual basis a unified system of fees, including
fees for health professionals [24].
The POS covers services, procedures, pharmaceuticals, and
others and, since 2008, has to provide the same coverage for both
contributory and subsidized systems. All that is not included in
the benefit plan (POS) is reimbursed by the Fund for Solidarity
and Guarantees. There are two approaches to obtain reimburse-
ment in Colombia: the first is through a scientific panel (comisio´n
te´cnico cientı´fica), and the second is through legal actions for the
protection of fundamental rights (tutelas) [25].
In 2010, a bill was passed to Senate to eliminate reimburse-
ment. In 2011, the Ministry of Social Protection passed the
resolution 3026/2011 that establishes maximum reimbursement
values for pharmaceuticals not included in the benefit plans
made by Fund for Solidarity and Guarantees [25,26].
Although there is a growing need to perform HTA to assist in the
decision-making process for reimbursement, Colombia has never
used pharmacoeconomics to inform reimbursement decisions in
the country. Currently, there is a methodological guideline for the
development of evidence-based clinical practice guidelines. This
methodological guideline includes a chapter on economic evalua-
tion of clinical recommendations (not reimbursement). In 2011, law
1438, which amends the social security system in health, stated
that it ‘‘Empowers the Ministry of Social Protection, to create an
Institute for Health Technology Assessment, which is to be a non-
Table 1 – Characteristics and differences of health care systems and HTA in four Latin American countries.
Mexico Brazil Argentina Colombia
Health care system Public and private Public and private Public and private Public and private









In 2003, CMED was
created to evaluate
cost of drugs approved
in the country. HTA
was established in
Brazil in 2006, and it is
now responsibility of
the CONITEC (2011).
There is no centralized/
national HTA system
in place.
There is no HTA system
in place. HTA decisions
in Colombia are based
on data from NICE.
ANMAT, Administracio´n Nacional de Medicamentos, Alimentos y Tecnologı´a Me´dica; ANVISA, Ageˆncia Nacional de Vigilaˆncia sanita´ria;
CENETEC, Centro Nacional de Excelencia Tecnolo´gica en Salud; CMED, Chamber of Medicine; COFEPRIS, Comisio´n Federal Para la Proteccio´n
Contra los Riesgos Sanitarios; CONITEC, Comiss ~ao Nacional de Incorporac- ~ao de Tecnologias; HTA, health technology assessment; INVIMA,
Instituto Nacional de Vigilancia de Medicamentos y Alimentos; NICE, National Institute for Health and Clinical Excellence.
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the risk in Colombia, there are a number of methods for risk
adjustment such as co-payment and premium adjustment by age,
region, and gender. Similar to Argentina, Colombia has no experi-
ence in payment for performance contracts or conditional reim-
bursement with the device or pharmaceutical industry.
At this point, the impact of economic and humanistic data is
currently considered only for clinical practice guidelines; as an
example, a budget impact analysis was done to update the POS
but was not used by the CRES. There are no centers of excellence
in Colombia, but only small groups with minimal experience. At
this time, the National Institute for Health and Clinical Excel-
lence has great influence; it is the official consultant for the
development of clinical practice guidelines in Colombia.Comparison of Health Care Systems and HTA in the
Four Countries
Table 1 shows a summary of the main characteristics and differ-
ences in terms of HTA implementation in the four Latin American
countries that are being discussed in this article. Although all
countries have similar health care systems, with a mix of public
and private sector, only Mexico and Brazil have a national agency
responsible for HTA in their respective countries. In Argentina, there
are several HTA agencies; however, there is no centralized agency to
provide decisions for the entire country. Colombia does make
reimbursement decisions; however, this is not dependent on sub-
mitted cost and pharmacoeconomic studies but on decisions made
by the National Institute for Health and Clinical Excellence—the UK
agency—to inform decisions made in its own country.
It is also important to mention that none of the countries listed
in this article makes decisions regarding drug approval on the basis
of cost but on efficacy and safety. Still, cost discussions by the
regulatory agencies are needed to establish the drugs that will be
eligible to enter the formulary of each country, and consequently
have their cost reimbursed by the public sector of the country.
There is a clear trend reflecting the importance that Latin
American health care systems are paying to the concept of
incorporating new technologies that are viewed as offering good
value proposition.
It is evident that HTA has been formally used to shape benefit
packages in a number of Latin American countries. Pharmacoe-
conomic guidelines are more apparent among some of the four
Latin American countries (Brazil and Mexico) for their local needs
in terms of regulation along with common country unions.In the future, the Latin American region needs to increase
drug access along with implementing cost-containment mea-
sures in their public sector, to improve quality and health
outcomes for the population. Moreover, the health care decisions
such as approval of drugs and interventions will need to account
not only for safety and efficacy but also cost to ensure better
economic outcomes in a region with limited resources.
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